Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Darleukin/fibromun - Philogen

Drug Profile

Darleukin/fibromun - Philogen

Alternative Names: Daromun; L19-IL2 + L19-TNF; L19IL2-L19TNF; L19IL2/L19TNF

Latest Information Update: 26 Dec 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Philogen
  • Class Antineoplastics; Cytokines; Monoclonal antibodies; Recombinant fusion proteins
  • Mechanism of Action Angiogenesis inhibitors; Antibody-dependent cell cytotoxicity; Immunostimulants; Interleukin-2 receptor agonists; Tumour necrosis factor alpha stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Malignant melanoma
  • Preclinical Solid tumours

Most Recent Events

  • 31 Oct 2018 Preclinical trials in Solid tumours in Italy (Philogen pipeline, October 2018)
  • 31 Oct 2018 Philogen plans clinical trials for Solid tumours (Philogen pipeline, October 2018)
  • 20 Sep 2018 Philogen initiates the phase III Neo-DREAM trial for Melanoma in USA (Late-stage disease, Metastatic disease, Neoadjuvant therapy) (Intratumoural) (NCT03567889)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top